Zealand Pharma released Phase 2 data for petrelintide, an amylin analog partnered with Roche, showing up to ~10.7% mean weight loss at 42 weeks with what Zealand characterized as "placebo‑like" tolerability. Roche will continue development under the existing partnership while the data feed discussions about differentiated efficacy and side‑effect profiles in the fast‑moving obesity and metabolic space. The readout reinforces amylin analogs as a credible competitor to GLP‑1 and GIP/GLP combinations and may influence commercial and regulatory positioning for next‑generation metabolic agents. For Roche and Zealand, the dataset supports a tolerability narrative that could ease payer and prescriber conversations compared with some earlier obesity regimens.